Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).